The proportion of patients with 24-week confirmed disability after six years of Tecfidera treatment was 15.7% vs. 24.3% in those who switched to Tecfidera treatment in year three. This represents a 49% reduction of disability risk (P=0.0397) at year six for those who started Tecfidera treatment from the beginning, compared to those who started treatment later after two years of placebo.

Tecfidera is an oral therapy currently approved for the treatment of relapsing forms of MS, including relapsing-remitting MS, the most common form.

For more information call (617) 679–2000 or visit Biogen.com.